Keystone Symposia

This meeting took place in 2011



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Drugs from Bugs: The Anti-Inflammatory Drugs of Tomorrow (Z1)


Organizer(s) Padraic G. Fallon, Grant McFadden and Amanda E.I. Proudfoot Fichard
April 3—7, 2011
Snowbird Resort • Snowbird, UT USA
Abstract Deadline: Dec 2, 2010
Late Abstract Deadline: Jan 4, 2011
Scholarship Deadline: Dec 2, 2010
Early Registration Deadline: Feb 3, 2011

Supported by the Directors’ Fund


Summary of Meeting:
A recent global trend is that fewer novel therapeutics are progressing from the biopharmaceutical pipeline to the clinic. This has prompted the drug research and development sector to adopt less conventional approaches in broadening the search for new drugs. In this meeting we will examine the growing opportunities for discovery of novel drugs from pathogens, or the “drugs from bugs” approach. The genome of man is the product of the evolution of humans adapting to environmental factors, with infectious pathogens exerting potent selective pressure. Some of the major immune-mediated diseases of today are associated with genes that evolved to respond to pathogens. Novel therapeutic strategies and new drugs can be developed by both understanding how pathogens modulate and usurp the immune system, and also by identifying the functional molecules from pathogens. Indeed, a new generation of pathogen-derived immune modulating molecules is now in clinical trials. In this meeting leading experts will present the current status of the use of pathogens as a depository for new therapeutics. This forum will be an opportunity for industry to engage with academics for the development of novel strategies for drug discovery. This meeting will bring together cross-disciplinary scientists to exchange and share ideas, and thereby foster collaborations on the generation of new drug strategies for the future.

View Meeting Program

Scholarships/Awards


KS/ABRCMS Travel Award Recipients


Norris Hollie
University of Cincinnati, Metabolic Diseases Institute, USA